单中心异基因造血干细胞移植后淋巴增殖性疾病临床观察
回顾性分析35例allo-HSCT后PTLD患者,其中临床诊断11例、病理确诊24例,并按WHO-HAEM5重新命名。单形性PTLD总生存率仅54.5%(6/11),死亡患者原发病均为重型再生障碍性贫血(SAA),提示SAA相关PTLD预后差,需更积极干预。
要点
- allo-HSCT后PTLD中单形性PTLD预后最差,总生存率54.5%(6/11)。
- 死亡PTLD患者原发病均为SAA,4例死于PTLD爆发式进展。
- 原发病为SAA的PTLD患者需更积极的临床干预策略。
核心结论
- 原发病为SAA的PTLD患者预后差,临床需采取更积极的干预策略。
研究设计与样本
- 回顾性分析中国人民解放军总医院第五医学中心2016年1月1日至2024年12月15日allo-HSCT后诊断PTLD的35例患者临床资料。
- 35例中临床诊断11例,病理确诊24例;24例病理确诊PTLD按WHO-HAEM5最新命名方式重新命名。
主要发现
- 单形性PTLD对应淋巴瘤亚型PTLD,该组患者预后最差,总生存率仅为54.5%(6/11)。
- 死亡患者原发病均为重型再生障碍性贫血(SAA),1例死于化疗相关并发症,其余4例死于PTLD爆发式进展。
关键数值与推荐
- 单形性PTLD总生存率为54.5%(6/11)。
临床怎么用
- 对原发病为SAA的PTLD患者,临床需考虑更积极的干预策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To analyze the clinical characteristics of post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) lymphoproliferative disorders and to explore the clinical guidance provided by the latest nomenclature for post-transplant lymphoproliferative disorders (PTLD) in the 2022 World Health Organization Classification of Hematologic and Lymphoid Tumors (WHO-HAEM5). A retrospective analysis was conducted on the clinical data of 35 patients diagnosed with PTLD after allo-HSCT at the Department of Hematology, Fifth Medical Center, Chinese PLA General Hospital, from January 1, 2016, to December 15, 2024. Among these, 11 cases were clinically diagnosed, and 24 cases were pathologically confirmed. The 24 pathologically confirmed PTLD cases were renamed according to the latest WHO-HAEM5 nomenclature. Monomorphic PTLD, corresponding to the lymphoma subtype of PTLD, exhibited the poorest prognosis with a over survival rate of only 54.5% (6/11). All deceased patients had severe aplastic anemia (SAA) as the primary disease; one death resulted from chemotherapy-related complications, while the remaining four died due to explosive PTLD progression. PTLD patients with SAA as the primary diagnosis exhibit poor prognosis, necessitating more aggressive clinical intervention strategies. 为了分析异基因造血干细胞移植(allo-HSCT)后淋巴增殖性疾病的临床特征并探讨2022年世界卫生组织第五版《造血与淋巴组织肿瘤分类》(WHO-HAEM5)对移植后淋巴增殖性疾病(PTLD)的最新命名方式的临床指导意义,本文回顾性分析中国人民解放军总医院第五医学中心血液病医学部自2016年1月1日至2024年12月15日行allo-HSCT后诊断为PTLD的35例患者临床资料,其中临床诊断11例,病理确诊24例;24例病理确诊的PTLD按WHO-HAEM5最新命名方式重新命名。单形性PTLD,对应淋巴瘤亚型PTLD,该组患者预后最差,总生存率仅为54.5%(6/11),死亡患者原发病均为重型再生障碍性贫血(SAA),1例死于化疗相关并发症,其余4例均死于PTLD爆发式进展。原发病诊断为SAA的PTLD患者预后差,临床需采取更积极的干预策略。.
引用
- Qiao ZQ, Sun Y, Shi YP, et al. [Clinical observation of posttransplant lymphoproliferative disorder in a single center]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41486662. doi:10.3760/cma.j.cn121090-20250319-00141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。